Patents by Inventor William T Tino

William T Tino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10512682
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: December 24, 2019
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Publication number: 20190125853
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 2, 2019
    Inventors: Charles RICHARDSON, Thomas S. VEDICK, Thomas R. FOUBERT, William T. TINO
  • Patent number: 10010599
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9861691
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 9, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9308249
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 12, 2016
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9272028
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 1, 2016
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Publication number: 20160008455
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 14, 2016
    Inventors: Charles RICHARDSON, Thomas S. VEDVICK, Thomas R. FOUBERT, William T. TINO
  • Publication number: 20130273148
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: Charles RICHARDSON, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 8431116
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: April 30, 2013
    Assignee: Takeda Vaccines (Montana), Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Publication number: 20120156243
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: June 16, 2010
    Publication date: June 21, 2012
    Applicant: LigoCyte Pharmaceutical
    Inventors: Charles RICHARDSON, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 7955603
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: June 7, 2011
    Assignee: Ligocyte Pharmaceuticals, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 7476513
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: January 13, 2009
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William T. Tino
  • Publication number: 20080299152
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: September 28, 2007
    Publication date: December 4, 2008
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 7201900
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: April 10, 2007
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William T Tino